公告称，本期间溢利下降主要是苏州东瑞善丰路厂区和兰州东瑞未形成规模化的商业化生产、"安"系列 等集采品种受国家政策影响部分省份价格下降以及研发费用增加所致。 其中：治疗高血压的"安"系列产品与去年同期相比销售量减少 5.7%，销售额下降 22.1%， 主要是受国 家集采政策影响部分地区价格下降;抗病毒药恩替卡韦分散片与去年同期相比销售量增长 14.0%，销售 额增长 8.7%;以治疗高血脂症为主的福建东瑞产品系列与去年同期相比销售量增长 19.5%，销售额增长 16.6%;头孢粉针剂与去年同期相比，销售量增长 47.9%，销售额增长 55.7%;随着集团全资附属公司苏州 东瑞制药有限公司(苏州东瑞)善丰路厂区和集团全资附属公司兰州东瑞制药有限公司陆续商业化投产， 中间体及原料药与2024年同期相比销售量增长 244.8%，销售额增长 142.7%。 智通财经APP讯，东瑞制葯(02348)公布2025年中期业绩，收入约6.3亿元，同比增长9.2%;毛利约3.14亿 元，同比减少7.1%;母公司拥有人应占溢利约1.05亿元，同比减少78.79%;每股盈利0.06961元，每股中期 股息0.015港元。 ...

报告期内，集团防黏连及止血产品线收入较2024年同期增长约人民币4110万元，增幅约59.68%，主要 是集团「康瑞胶」产品于2024年12月被纳入《上海市生物医药「新优药械」产品目录》(第四批)。纳入 目录的产品可获得上海公立医院准入绿色通道，同时优先获得上海医保谈判推荐资格，加速进入地方医 保目录，提高患者支付意愿。报告期内，集团迅速完成「康瑞胶」产品在上海、河南等部分地区的市场 准入、打开了营销新局面。 格隆汇8月22日丨昊海生物科技(06826.HK)公布中期业绩，截至2025年6月30日止六个月，集团共录得营 业收入约人民币12.93亿元，同比减少约7.48%；集团研发开支约人民币9840万元，同比下降约21.53%， 集团研发开支占收入比重为7.61%；公司普通股权益持有人应占利润约为人民币2.11亿元，同比下降约 10.29%。每股基本盈利为人民币0.91元。董事会宣派中期股息为每股人民币0.40元(含税)。 报告期内，集团紧密围绕医美、眼科、骨科、防黏连及止血四大核心业务板块，积极应对外部环境的机 遇与挑战，持续深化产品创新、市场拓展和精益管理，集团整体经营继续保持了稳健发展态势。报告期 内， ...

Group 1 - The company expects a net loss for the period from January 1, 2025, to June 30, 2025, with an estimated loss ranging from 30 million to 39 million yuan, compared to a profit of 37.8015 million yuan in the same period last year, representing a decline of 179.36% to 203.17% [1] - The company anticipates a net profit attributable to shareholders of the listed company to be between a loss of 38 million to 46 million yuan, with a significant decrease in net profit after deducting non-recurring gains and losses, expected to be a loss of 38 million to 46 million yuan compared to a profit of 31.4786 million yuan last year, reflecting a decline of 220.72% to 246.13% [1] - Basic earnings per share are projected to be a loss of 0.09 to 0.12 yuan per share, compared to a profit of 0.11 yuan per share in the previous year [1] Group 2 - The main reasons for the performance decline include the impact of pharmaceutical industry policies and market factors, particularly the national centralized procurement policy, which led to a significant decrease in sales volume of the main profit-generating product, Rabeprazole Sodium Enteric-coated Capsules, as well as varying impacts on sales volume and prices of other major formulation products, resulting in a decline in gross profit [1] - The sales prices of major raw materials have also significantly decreased due to domestic and international market competition, contributing to a decline in both operating revenue and product profitability compared to the previous year [1]

Core Viewpoint - Wuhan Dazhong Dental Medical Co., Ltd. has submitted a second application for listing on the Hong Kong Stock Exchange, marking another attempt at capitalizing after its first application lapsed due to not completing the listing within six months [1][2]. Business Layout and Market Position - Founded in 2007 by Yao Xue, the company operates 92 medical institutions, including 4 hospitals and 80 outpatient departments, primarily in Hubei and Hunan provinces, establishing a community-centered service network [1]. - According to Frost & Sullivan, Dazhong Dental ranks first among private dental service providers in Central China, with a market share of approximately 2.6% based on 2023 revenue [1]. - The company's main business segments include comprehensive dental services, dental implant services, and orthodontic services, with comprehensive dental services accounting for over 50% of total revenue [1]. - The company has demonstrated strong customer retention, with a revisit rate increasing from 75.3% in 2022 to 79.6% in 2024 [1]. Financial Performance and Challenges - The company has experienced revenue fluctuations, with revenues of 409 million yuan, 442 million yuan, and 407 million yuan from 2022 to 2024, respectively [2]. - Net profit attributable to shareholders was 43.3 million yuan, 50.1 million yuan, and 41.9 million yuan for the same years, with a noticeable decline in 2024 [2]. - The gross profit margin decreased from 38.1% in 2023 to 37.4% in 2024 [2]. - The decline in performance is attributed to slow economic recovery post-pandemic and intensified competition in the dental service industry, leading to a drop in average transaction prices across all main business segments [2]. - The average cost of dental implant services fell over 30%, from 8,460 yuan in 2022 to 5,767 yuan in the first half of 2024, influenced by national procurement policies [2]. - Prior to the listing application in September 2024, original investors, including CITIC Securities, chose to exit, leading the company to repurchase 8.3793 million shares for 121 million yuan [2].